http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
SOHN, EUN JEONG,SHIN, MIN JEA,EUM, WON SIK,KIM, DAE WON,YONG, JI IN,RYU, EUN JI,PARK, JUNG HWAN,CHO, SU BIN,CHA, HYUN JU,KIM, SANG JIN,YEO, HYEON JI,YEO, EUN JI,CHOI, YEON JOO,IM, SEUNG KWON,KWEON, HA Spandidos Publications 2016 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE Vol.38 No.1
<P>Oxidative stress-induced apoptosis is associated with neuronal cell death and ischemia. The NOL3 [nucleolar protein 3 (apoptosis repressor with CARD domain)] protein protects against oxidative stress-induced cell death. However, the protective mechanism responsible for this effect as well as the effects of NOL3 against oxidative stress in ischemia remain unclear. Thus, we examined the protective effects of NOL3 protein on hydrogen peroxide (H2O2)-induced oxidative stress and the mechanism responsible for these effects in hippocampal neuronal HT22 cells and in an animal model of forebrain ischemia using Tat-fused NOL3 protein (Tat-NOL3). Purified Tat-NOL3 protein transduced into the H2O2-exposed HT22 cells and inhibited the production of reactive oxygen species (ROS), DNA fragmentation and reduced mitochondrial membrane potential (Delta(Psi m)). In addition, Tat-NOL3 prevented neuronal cell death through the regulation of apoptotic signaling pathways including Bax, Bcl-2, caspase-2, -3 and -8, PARP and p53. In addition, Tat-NOL3 protein transduced into the animal brains and significantly protected against neuronal cell death in the CA1 region of the hippocampus by regulating the activation of microglia and astrocytes. Taken together, these findings demonstrate that Tat-NOL3 protein protects against oxidative stress-induced neuronal cell death by regulating oxidative stress and by acting as an anti-apoptotic protein. Thus, we suggest that Tat-NOL3 represents a potential therapeutic agent for protection against ischemic brain injury.</P>
Poster Session 3 / N-16 : Screening of chemokine receptor interacting protein by two hybrid system
(Jee Won Joung),(Sook Yeon Lee),(Seung Hwa Hong),(Won Shin),(Ho Jung Oh),(Young Ju Choi),(Jae Ho Jin),(Seon Mi Kim),(Hong Ki Min),(Yeo Won Sohn),(Jung Woo Kim) 생화학분자생물학회 1999 생화학분자생물학회 춘계학술발표논문집 Vol.- No.-
N/A
재조합 사람성장호르몬(소바트로핀)의 KFDA표준품(KS 98/674) 설정연구
신원(Won Shin),정지원(Jee Won Joung),진재호(Jae Ho Jin),Adrian F. Bristow,손여원(Yeo Won Sohn) 대한약학회 2001 약학회지 Vol.45 No.2
The complexity and variability of both the biologicals and the bioassays used to test them led to the use of the reference standard- a sample of the product of defined purity and potency, against which all preparations of that product must be calibrated. In order to prepare and establish KFDA reference standard for recombinant human growth hormone(somatropin), somatropin substance was filled in ampoules in National Institute for Biological Standards and Control(NIBSC). The candidate KFDA reference standard for somatropin(designated as 98/674) was evaluated to determine the suitability of serving as a KFDA reference standard for somatropin by the collaborative study, in which 10 laboratories participated. Physicochemical analysis and in vivo bioassay were performed by direct comparison with the international somatropin standard 88/624. 98/674 was identified as somatropin by SDS-PAGE, IEF, peptide mapping, and HPLC. Determination of somatropin content by SE-HPLC yielded a mean estimate of 2.01mg somatropin per ampoule. Data from the study also yielded mean values of 0.39+/-0.26% for high molecular weight impurities by SE-HPLC and mean values of 2.13 +/- 1.29 % for somatropin related proteins by RP-HPLC. Estimates of relative potency by weight gain bioassay in the hypophysectomised rats showed that relative potency of KS 98/674 was 1.07 against IS 88/624. Based on the results of the collaborative study, the candidate reference standard for somatropin is suitable to serve as a KFDA reference standard for somatropin.
( Eun Ji Yeo ),( Won Sik Eum ),( Hyeon Ji Yeo ),( Yeon Joo Choi ),( Eun Jeong Sohn ),( Hyun Jung Kwon ),( Dae Won Kim ),( Duk-soo Kim ),( Sung-woo Cho ),( Jinseu Park ),( Kyu Hyung Han ),( Keun Wook L 한국응용약물학회 2021 Biomolecules & Therapeutics(구 응용약물학회지) Vol.29 No.3
Oxidative stress plays a crucial role in the development of neuronal disorders including brain ischemic injury. Thioredoxin 1 (Trx1), a 12 kDa oxidoreductase, has anti-oxidant and anti-apoptotic functions in various cells. It has been highly implicated in brain ischemic injury. However, the protective mechanism of Trx1 against hippocampal neuronal cell death is not identified yet. Using a cell permeable Tat-Trx1 protein, protective mechanism of Trx1 against hydrogen peroxide-induced cell death was examined using HT-22 cells and an ischemic animal model. Transduced Tat-Trx1 markedly inhibited intracellular ROS levels, DNA fragmentation, and cell death in H<sub>2</sub>O<sub>2</sub>-treatment HT-22 cells. Tat-Trx1 also significantly inhibited phosphorylation of ASK1 and MAPKs in signaling pathways of HT-22 cells. In addition, Tat-Trx1 regulated expression levels of Akt, NF-κB, and apoptosis related proteins. In an ischemia animal model, Tat-Trx1 markedly protected hippocampal neuronal cell death and reduced astrocytes and microglia activation. These findings indicate that transduced Tat-Trx1 might be a potential therapeutic agent for treating ischemic injury.
손여원,신원,정자영,최영주,정지원,오일웅,진재호,박선영,박태성 식품의약품안전청 2000 식품의약품안전청 연보 Vol.4 No.-
우리나라에서 유통되고 있는 재조합 인터페론 알파의 역가시험을 표준화하기 위하여 국내제조 5개사,수입 1개사 및 식품의약품안전청이 참여하여 공동연구를 실시하였다. 공동연구 참여사의 역가시험법의 상대적인 감도와 상용표준품의 활성을 비교 ·보정하기 위하여 공통의 인터페론 알파 시험물질에 대하여 5회 이상의 독립적인 시험들 실시하고 시험결과의 정확도, 정밀포 및 재현성을 비교하였다. 보다 정확한 분석을 위하여 모든 참여사는 자사 제품의 품질관리에 적용되고 있는 역가시험법과 더불어 식품의약품안전청에서 제공한 참조씨험법을 함께 시험하였고 시험결과를 자사의 계산법과 동시에 평행선분석법으로 각각 계산하여 그 차이를 비교하였다. 그 결과 시험의 정밀도와 재현성은 각 참여사의 자사 뵉가시험법과 평행선분석법을 적용하였을 째 보다 우수하게 나타났고 대부븐의 참여사에서 1표시역가의 80%~l%', 신뢰구간 '표시울가의 64%~l56%' 내에 분포하여 상대적인 감도가 고르면서 정확포가 높았다. 또한 각 참여사의 자사 결과계산법과 평행선분석법 간의 차이를 't-Test'로 분석한 결과 유의한 차이를 나타내지 않았으며 모든 찹여사의 두 가지 시험법과 분석법으로부터 얻은 평균값들의 차이를 분석한 결과 유의한 차이를 나타내지 않아 모든 참여사의 인터페론 역가시헌이 '표준화'되어 있는 것으로 분석되었으며 평행선분석법 및 신뢰구간에 대한 적용가능성을 제시하였다. The specific activiw of recombinant interferons made by different manufacturers can vary and bioassay systems which are utilized to determine the biological potency ofinterferon may he affected by a number of factors, such as ceIB lines, viruses and the statisticalanalysis of the assay. Tllerefore the bioassay of interferon, like as other biological products, isessentially comparative and thus requires a fHxed reference standard and standardized assayconditions. A collaborative study was performed for standardization of interferon bloassay. Sixlaboratories of interferon Danufacturers and KFDA were participated in this study. Alllaboratories measured the potency of'the same inteferon samples'by their own routinemethods and the reference method which was offered by KFBA. The results were analysed byboth ways using their own data analysis methods and the usual statistical methods for aparallel line assay The relatiue sensitivities of each assay system and the potency of eachworking standard of the participants were compared by assessing the assay performance svchas accuracy, precision and reproducibility. The results showed best pr·ecision and reproducibiBitywhen the potency was measured by the manufacturer's routine methods and calculated byparallel line analysis. Tte estimated potency was from 80% to 125% and the confidence limitwas from 64% to 156% of the stated potency in most laboratofes, which showed goodaccuracy. Differences in data analysis between the manufacturer's routine analytical method andthe Parallel line assay were not significant by't-Test'and differences in all results fromroutine assay and reference assay also were not significant by'analysis of valiance'. Based onthe results of the collaboriltive study, all participants were'standardized'in the interferonbioassay and we may consider the change of the data analysis of Inteferon potency to thestatistical method for a parallel line assay.
( Yoomi Yeo ),( Ji-yong Moon ),( Hyun Lee ),( Jiin Ryu ),( Sung Jun Chung ),( Tai Sun Park ),( Dong Won Park ),( Sang-Heon Kim ),( Tae Hyung Kim ),( Jang Won Sohn ),( Ho Joo Yoon ) 대한결핵 및 호흡기학회 2020 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.128 No.-
Background Asthma patients often have coexisting pulmonary comorbidities that are associated with severe presentation, poor quality of life, and more health care resource use. However, except for chronic obstructive pulmonary disease (COPD), the impact of coexisting pulmonary comorbidities on mortality in patients with asthma has not been comprehensively evaluated using nationally representative data. Methods Using a nationally representative sample database, we performed a retrospective cohort study of patients with asthma and age- and sex-matched cohort. We estimated hazard ratio (HR) and 95% confidence interval (CI) for mortality comparing the asthma cohort with the matched cohort. Results During a median of 8.9 follow-up duration, the overall mortality rate was higher in the asthma cohort than in the matched cohort (1,312/100,000 person-years vs. 1,174/100,000 person-years, p <0.001). The HR for mortality in the asthma cohort relative to the matched cohort asthma was 1.13 (95% confidence interval [CI], 1.07-1.19), which was especially higher in males (HR = 1.22, 95% CI = 1.13-1.31) and patients under 60 years (HR = 1.25, 95% CI = 1.10-1.42). Comorbid respiratory diseases further increased mortality of patients in the asthma cohort compared to those in the matched cohort (adjusted HR = 2.94, 95% CI = 2.75-3.14 for COPD; adjusted HR = 2.50, 95% CI = 2.07-3.02; adjusted HR = 7.30, 95% CI = 4.60-11.58 for lung cancer; and adjusted HR = 1.92, 95% CI = 1.75-2.09 for pneumonia). Conclusions Patients with asthma had a higher mortality rate compared to those without asthma, especially in males and those under 60 years. Coexisting pulmonary comorbidities, including COPD, bronchiectasis, lung cancer, and pneumonia, primarily explained the higher mortality in patients with asthma compared to those without asthma.
Development of dietary pattern evaluation tool for adults and correlation with Dietary Quality Index
Cheongmin Sohn,Yeo Jin Cho,Misung Kim,Kyung-Suk Choi,Kyung Won Kim,Yeo Do Lee 대한지역사회영양학회 2016 Nutrition Research and Practice Vol.10 No.3
BACKGROUND/OBJECTIVES: As the prevalence of chronic diseases has risen, the need for straightforward diagnostic tools for monitoring nutrition status to improve nutrition counseling and disease prevention has likewise increased. This study developed an easily usable dietary behavior pattern diagnosis checklist and investigated its correlation with dietary quality index. SUBJECTS/METHODS: A draft dietary pattern evaluation tool was generated by analyzing previous studies. The draft questionnaire comprised 61 questions for assessing dietary habits. A survey was administered to 320 adults (19 to 64 years old) using the dietary pattern evaluation tool and 24-hour-recall method between March and May of 2014 in Jeonbuk province and the metropolitan area. Principal component analysis with varimax rotation was performed to identify dietary behavior patterns. Nutritional analysis was conducted using CAN-Pro 4.0, and the Diet Quality Index-International (DQI-I) was calculated to assess dietary quality. The correlation between dietary pattern scores and DQI-I scores was also analyzed. RESULTS: The factor analysis resulted in a total of 34 questions mapped to four main dietary behavior patterns: “high fat and calorie” pattern (12 questions), “overeating/binge” pattern (nine questions), “dietary impulse” pattern (eight questions), and “unbalanced food intake” pattern (five questions). The four dietary behavior patterns were negatively correlated with DQI-I adequacy and total scores (P < 0.01). CONCLUSIONS: The dietary pattern evaluation tool developed in this study can be used to diagnose a client’s dietary behavior problems and is available as a nutrition counseling tool in the field.